Welcome to our dedicated page for Entero Therapeutics news (Ticker: ENTO), a resource for investors and traders seeking the latest updates and insights on Entero Therapeutics stock.
Entero Therapeutics Inc., now GridAI Technologies Corp., reports developments tied to its completed acquisition of Grid AI and its change from a gastrointestinal therapeutics issuer to an AI-driven energy-infrastructure software company. Grid AI operates as a wholly owned subsidiary with a grid-edge software and controls platform for utilities, retail energy providers and large power users managing load and distributed energy resources, including battery energy storage systems.
Company news has centered on the name and ticker transition, Nasdaq compliance matters, Grid AI platform commercialization, data-center power orchestration, and legacy biopharmaceutical disclosures involving Adrulipase, a recombinant lipase enzyme program for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis.
Entero Therapeutics, a biopharmaceutical company specializing in gastrointestinal (GI) disease therapies, will provide a corporate update at the 2024 BIO International Convention, held from June 3-6 in San Diego, CA. The company will present on June 4 at 10:30 a.m. PDT in Presentation Theater 4. The focus will be on their Phase 3 treatment for celiac disease. Interested parties can schedule meetings via the BIO One-on-One Partnering platform.
Entero Therapeutics presented two posters highlighting celiac disease research at the 2024 Digestive Disease Week Conference. The first presentation introduced the VCIEL scale, a new quantitative measure combining the villus height to crypt depth ratio (Vh:Cd) and intraepithelial lymphocyte density (IEL), showing improved sensitivity and accuracy in diagnosing small intestinal mucosal health. The second presentation focused on gluten intake thresholds needed to trigger positive serological responses, revealing higher levels than previously thought. These findings aim to enhance diagnostics and inform Phase 3 clinical trials for latiglutenase, their investigational celiac disease treatment.